A. Karim Kader, MD, PhD, FRCSC, presented “AI in Healthcare: The Hype, The Reality, and the Promise” during the 34th International Prostate Cancer Update on February 13, 2024, in Vail, Colorado.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Kader, A. Karim. “AI in Healthcare: The Hype, The Reality, and the Promise.” February 2024. Accessed Nov 2024. https://grandroundsinurology.com/ai-in-healthcare-the-hype-the-reality-and-the-promise/
AI in Healthcare: The Hype, The Reality, and the Promise – Summary
A. Karim Kader, MD, PhD, FRCSC, explores the current state and future potential of artificial intelligence (AI) in healthcare. Dr. Kader begins by analyzing AI’s role in transforming current medical practice.
Dr. Kader acknowledges AI’s benefits, including its potential to revolutionize diagnostics, treatment planning, and patient care. When acting as a “scribe,” AI can be invaluable in creating grant proposals, patient education materials, and the writing of operative notes.
Looking ahead, Dr. Kader envisions a future where AI is seamlessly integrated into routine clinical practice, augmenting the capabilities of healthcare professionals and enhancing patient care. He calls for continued investment in AI research, interdisciplinary collaboration, and the development of robust frameworks for AI implementation and governance.
About The 34th Annual International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. The 34th iteration of the meeting occurred February 11-14, 2024 in Vail, Colorado. To view more educational presentations from IPCU 34, visit our collection page.
ABOUT THE AUTHOR
A. Karim Kader, MD, PhD, is a board-certified urologist who specializes in screening, detecting, treating and preventing prostate cancer. He has successfully a genetic test to predict lifetime risk of developing prostate cancer. As a Professor in the Department of Urology and Director of Urologic Oncology at the University of California, San Diego, Dr. Kader instructs medical students, residents and fellows at UC San Diego School of Medicine. His current research interests include artificial intelligence in healthcare and the use of augmented reality and enhanced imaging techniques for education and improved surgical outcomes. Dr. Kader completed a Fellowship in Urologic Oncology at the University of Texas MD Anderson Cancer Center in Houston and a Residency in Urology at the University of Toronto in Ontario, Canada. He earned his medical degree and doctoral degree from the University of British Columbia in Vancouver, British Columbia. Dr. Kader is nationally recognized for his expertise in performing robot-assisted radical cystectomy and urinary diversion for patients with bladder cancer. He holds several patents for genetic discoveries focused on the early detection and prevention of prostate cancer in addition to device patents for prostate cancer treatment. He is the principal investigator in numerous clinical research projects and has published extensively.
